Humacyte's (HUMA) "Buy" Rating Reiterated at D. Boral Capital

Key Points

• The investment analysts at D. Boral Capital have reiterated a "Buy" rating for Humacyte (NASDAQ:HUMA) with a price target of $25.00.
• Humacyte recently reported a loss of ($0.24) EPS for the quarter, missing analyst estimates, with revenues also below expectations at $0.30 million.
• Insider activity showed significant selling, with both the Director and CEO each selling 591,685 shares for a total of $934,862.30 each on August 20th.

Humacyte (NASDAQ:HUMA - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $25.00 price target on the stock.

HUMA has been the subject of a number of other research reports. Barclays initiated coverage on shares of Humacyte in a research note on Wednesday, August 27th. They issued an "overweight" rating and a $3.50 target price for the company. TD Cowen cut their target price on shares of Humacyte from $5.00 to $3.50 and set a "buy" rating for the company in a research note on Tuesday, August 12th. Wall Street Zen cut shares of Humacyte from a "hold" rating to a "sell" rating in a research report on Sunday, August 17th. Finally, HC Wainwright dropped their price objective on shares of Humacyte from $4.00 to $3.00 and set a "buy" rating for the company in a research report on Tuesday, August 12th. Seven analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Humacyte has an average rating of "Moderate Buy" and a consensus price target of $9.75.

Humacyte Stock Up 0.3%

Shares of HUMA opened at $1.48 on Monday. The stock has a market cap of $233.60 million, a price-to-earnings ratio of -3.30 and a beta of 1.88. The company has a quick ratio of 1.93, a current ratio of 2.45 and a debt-to-equity ratio of 2.97. Humacyte has a 12 month low of $1.15 and a 12 month high of $6.77. The company has a 50-day moving average price of $2.00 and a two-hundred day moving average price of $2.10.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.09). The business had revenue of $0.30 million for the quarter, compared to analysts' expectations of $0.94 million. Equities analysts predict that Humacyte will post -1.27 EPS for the current fiscal year.

Insider Activity at Humacyte

In related news, Director Brady W. Dougan sold 591,685 shares of the stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $1.58, for a total transaction of $934,862.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Laura E. Niklason sold 591,685 shares of the stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $1.58, for a total transaction of $934,862.30. The disclosure for this sale can be found here. Insiders have sold a total of 4,482,090 shares of company stock worth $7,466,382 in the last quarter. 5.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Humacyte

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Endowment Wealth Management Inc. lifted its stake in Humacyte by 5.1% in the 2nd quarter. Endowment Wealth Management Inc. now owns 109,458 shares of the company's stock valued at $229,000 after purchasing an additional 5,350 shares during the last quarter. Wealth Effects LLC raised its stake in shares of Humacyte by 5.8% during the second quarter. Wealth Effects LLC now owns 102,167 shares of the company's stock valued at $214,000 after acquiring an additional 5,600 shares during the last quarter. ProShare Advisors LLC raised its stake in shares of Humacyte by 24.1% during the second quarter. ProShare Advisors LLC now owns 31,493 shares of the company's stock valued at $66,000 after acquiring an additional 6,106 shares during the last quarter. MetLife Investment Management LLC lifted its holdings in Humacyte by 14.4% in the first quarter. MetLife Investment Management LLC now owns 51,442 shares of the company's stock valued at $88,000 after buying an additional 6,482 shares during the period. Finally, Concurrent Investment Advisors LLC lifted its stake in shares of Humacyte by 17.5% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 51,115 shares of the company's stock valued at $107,000 after purchasing an additional 7,615 shares during the period. Institutional investors own 44.71% of the company's stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.